Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPSG vs Aczone and Placebo in Acne Vulgaris
NCT03132194Phase 1Completed
- Start
- Aug 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of dapsone in acne vulgaris (3 arms). Primary endpoints: Change in inflammatory lesion counts at 12 weeks and Change in non-inflammatory lesion counts at 12 weeks. Started Aug 2016; status: completed.
02
Drugs
dapsone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03132194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132194.